Show simple item record

dc.contributor.authorJacobs, SE
dc.contributor.authorHickey, L
dc.contributor.authorDonath, S
dc.contributor.authorOpie, GF
dc.contributor.authorAnderson, PJ
dc.contributor.authorGarland, SM
dc.contributor.authorCheong, JLY
dc.contributor.authorProPremsStudy Groups
dc.date.accessioned2020-12-17T03:07:27Z
dc.date.available2020-12-17T03:07:27Z
dc.date.issued2017
dc.identifierpii: bmjpo-2017-000176
dc.identifier.citationJacobs, S. E., Hickey, L., Donath, S., Opie, G. F., Anderson, P. J., Garland, S. M., Cheong, J. L. Y. & ProPremsStudy Groups (2017). Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial.. BMJ Paediatr Open, 1 (1), pp.e000176-. https://doi.org/10.1136/bmjpo-2017-000176.
dc.identifier.issn2399-9772
dc.identifier.urihttp://hdl.handle.net/11343/254753
dc.description.abstractObjective: To determine the impact of one probiotics combination on the neurodevelopment of very preterm children at 2-5 years corrected gestational age (CA). Design: Follow-up study of survivors of a double-blinded, placebo-controlled, randomised trial of probiotic effects on late-onset sepsis in very preterm infants that found reduced necrotising enterocolitis. Setting: 10 tertiary perinatal centres in Australia and New Zealand. Patients: 1099 very preterm infants born <32 weeks' gestation and weighing <1500 g. Intervention: Probiotics (Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis) or placebo administered from birth until discharge home or term CA, whichever came sooner. Main outcome measures: Major neurodevelopmental impairment comprised any of moderate/severe cerebral palsy (Gross Motor Function Classification System score 2-5), motor impairment (Bayley-III Motor Composite Scale <-2SD or Movement Assessment Battery for Children <15th centile if >42 months' CA), cognitive impairment (Bayley-III Composite Cognitive or Language Scales <-2SD or Wechsler Preschool and Primary Scale of Intelligence Full Scale Intelligence Quotient <-2SD if >42 months' CA), blindness or deafness. Results: Outcome data were available for 735 (67%) participants, with 71 deaths and 664/1028 survivors assessed at a mean age of 30 months. Survival free of major neurodevelopmental impairment was comparable between groups (probiotics 281 (75.3%) vs placebo 271 (74.9%); relative risk 1.01 (95% CI 0.93 to 1.09)). Rates of deafness were lower in probiotic-treated children (0.6% vs 3.4%). Conclusion: Administration of the probiotics combination Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis to very preterm babies from soon after birth until discharge home or term CA did not adversely affect neurodevelopment or behaviour in early childhood. Trial registration number: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN012607000144415.
dc.languageeng
dc.publisherBMJ
dc.titleProbiotics, prematurity and neurodevelopment: follow-up of a randomised trial.
dc.typeJournal Article
dc.identifier.doi10.1136/bmjpo-2017-000176
melbourne.affiliation.departmentObstetrics and Gynaecology
melbourne.affiliation.departmentPaediatrics (RCH)
melbourne.source.titleBMJ Paediatrics Open
melbourne.source.volume1
melbourne.source.issue1
melbourne.source.pagese000176-
dc.rights.licenseCC BY-NC
melbourne.elementsid1323157
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862156
melbourne.contributor.authorAnderson, Peter
melbourne.contributor.authorDonath, Susan
melbourne.contributor.authorCheong, Jeanie
melbourne.contributor.authorJacobs, Susan
melbourne.contributor.authorOpie, Gillian
melbourne.contributor.authorWark, Suzanne
dc.identifier.eissn2399-9772
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record